Regeneron Says Antibodies Show Success in Preventing COVID-19 Infections

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, N.Y., on Sept. 17, 2020. Brendan McDermid/Reuters

Monoclonal antibodies that have already proven successful in preventing hospitalizations in people who contract COVID-19 may also serve as protection against COVID-19 infection, according to new data.

Regeneron said its monoclonal antibody treatment reduced the risk of contracting the disease by 81.6 percent among uninfected persons.